HCM
NKTR icon

Highbridge Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Highbridge Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,089
Closed -$1.33M – 1745
2015
Q2 		$1.33M Buy
+7,089
New +$1.22M 0.02% 639
2014
Q4 		– Sell
-728
Closed -$132K – 1347
2014
Q3 		$132K Buy
+728
New +$139K ﹤0.01% 1137
2013
Q4 		– Sell
-1,381
Closed -$216K – 1246
2013
Q3 		$216K Buy
+1,381
New +$255K ﹤0.01% 1153

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Highbridge Capital Management's NKTR Position: Q3 2015 in Review

Highbridge Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2015, closing a stake of 7,089 shares — an estimated $1.33M sold.

Highbridge Capital Management first reported a position in NKTR in Q3 2013 and held it in 3 quarters. The position peaked at $1.33M in Q2 2015. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

  • Highbridge Capital Management reported no remaining Nektar Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 7,089 Nektar Therapeutics shares in Q3 2015, an estimated $1.33M.
  • Highbridge Capital Management first reported a position in Nektar Therapeutics in Q3 2013 and held it in 3 quarters.
  • Highbridge Capital Management's Nektar Therapeutics position peaked at $1.33M in Q2 2015.
  • 166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.